Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Vertex supports JDRF’s Clinical Trial Connection Volunteer Program. The partnership helps educate, inform and match potential participants with active clinical trials that they may be eligible for and those that best align to the participant and trial desired outcomes. Vertex helps to further JDRF’s mission by serving as a member of JDRF’s Industry Advisory Panel.
We thank Vertex for all they do to help JDRF create a world without T1D.